Azienda Ospedaliera Pugliese Ciaccio
- Address
- Via Vinicio Cortese 25, 88100 Catanzaro, Italy
Hemic and Lymphatic Diseases
The research program at Azienda Ospedaliera Pugliese Ciaccio’s Haemophilia Center focuses on improving quality of life for patients with Haemophilia A. A long‑term study is evaluating how once‑weekly prophylaxis with a novel recombinant factor impacts daily activity and joint health.
- Weekly prophylactic factor replacement
- Monitoring of physical activity over two years
- Assessment of joint health and bleeding episodes
By integrating patient‑reported outcomes with clinical data, the site aims to demonstrate that sustained treatment can reduce joint damage and support more active lifestyles for adolescents and adults.
Neoplasms
In the oncology arm, investigators are studying Acute Myeloid Leukemia (AML) in children, adolescents, and adults. Trials explore whether new drug combinations such as CPX‑351 or the addition of Gemtuzumab‑Ozogamicin to standard chemotherapy can improve event‑free survival and remission rates.
- Novel chemotherapy regimens for de‑novo AML
- Targeted antibody‑drug conjugate therapy in relapsed AML
- Conditioning strategies for stem‑cell transplantation
- Collection of biological samples for toxicity and biomarker research
The site’s participation in an international multicenter trial reflects its commitment to advancing treatment options and reducing mortality for high‑risk leukemia patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Octapharma AG2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Octapharma AG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Pugliese Ciaccio
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2 | Celgene Corp. | Phase III | Not Recruiting | Jan 2023 | — |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 2 | Unknown | 2018-10-26 | 2022-12-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.